Telavancin
- Generic Name
- Telavancin
- Brand Names
- Vibativ
- Drug Type
- Small Molecule
- Chemical Formula
- C80H106Cl2N11O27P
- CAS Number
- 372151-71-8
- Unique Ingredient Identifier
- XK134822Z0
- Background
Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others...
- Indication
用于治疗革兰阳性菌耐甲氧西林金黄色葡萄球菌（MRSA）与甲氧西林敏感金黄色葡萄球菌引起的成人复杂性皮肤和皮肤结构感染，以及医院获得性和呼吸机相关细菌性肺炎(HABP/VABP)。
- Associated Conditions
- Bacterial Infections, Nosocomial Pneumonia, Ventilator Associated Bacterial Pneumonia (VABP), Complicated Skin and subcutaneous tissue bacterial infection
- Associated Therapies
- -
Pharmacokinetics of Telavancin in Normal and Obese Subjects
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 32
- Registration Number
- NCT02753855
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 8
- Registration Number
- NCT02392208
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
Telavancin Observational Use Registry (TOUR)
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 1063
- Registration Number
- NCT02288234
- Locations
- 🇺🇸
Newland Medical Associates, Southfield, Michigan, United States
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
- Conditions
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 121
- Registration Number
- NCT02208063
- Locations
- 🇺🇸
Remington-Davis Clinical Research, Columbus, Ohio, United States
Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT02013141
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's Mercy Hospital, Kansas City, Missouri, United States
Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2019-12-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT01321879
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT01238796
- Locations
- 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
VIBATIV Pregnancy Registry
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Cumberland Pharmaceuticals
- Registration Number
- NCT01130324
- Locations
- 🇺🇸
Cumberland Pharmaceuticals Inc., Nashville, Tennessee, United States
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 771
- Registration Number
- NCT00124020
- Locations
- 🇮🇱
Sheba Medical Center, Infectious Disease Unit, Tel Hashomer, Israel
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
- First Posted Date
- 2005-04-12
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 761
- Registration Number
- NCT00107952
- Locations
- 🇺🇸
Baystate Medical Center, Springfield, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.